CatalYm is a biopharmaceutical company developing novel cancer immunotherapies targeting Growth-and-Differentiation Factor 15 (GDF-15). Apart from its established role in cachexia, GDF-15 has been associated with immunosuppression in tissues and tumors and a rapidly growing body of literature supports the concept that GDF-15 is a major T cell repellent. CatalYm aims to neutralize GDF-15 to turn “cold” tumors “hot” and thereby substantially improving the efficacy of established immunotherapy such as anti-PD1/-PD-L1 checkpoint inhibitors. The company’s lead product candidate CTL-002, a neutralizing GDF-15 antibody, is set to enter clinical development in 2020.
Total raised: $111.12M
Investors 6
| Date | Name | Website |
| - | Vesalius B... | vesaliusbi... |
| 16.04.2022 | Jeito Capi... | jeito.life |
| - | BioGenerat... | biogenerat... |
| 09.01.2023 | Brandon Ca... | brandoncap... |
| - | Forbion | forbion.co... |
| - | Coparion | coparion.v... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 24.11.2022 | Series C | $52.03M | - |
| 11.11.2020 | Series B | $59.09M | - |
Mentions in press and media 16
| Date | Title | Description | Source |
| 06.12.2023 | CatalYm Presents Positive Phase 2a Outcome for Visugromab in... | Munich, Germany, December 6, 2023 – CatalYm announced that maturing Phase 2a results from its ongoin... | brandoncap... |
| 25.03.2023 | Her doctor said her severe morning sickness was all in her h... | Taped above a tidy wooden desk in the corner of her bedroom, right at eye level, is a piece of paper... | channelnew... |
| 24.11.2022 | German biotech startup CatalYm secures €50M to develop immun... | Bayern-based CatalYm, a biotechnology company developing immunotherapies for cancer patients, announ... | siliconcan... |
| 22.11.2022 | Forbion Portfolio Company CatalYm Closes EUR 50 Million Seri... | Naarden, The Netherlands, November 22, 2022 – Forbion portfolio company CatalYm today announced the ... | forbion.co... |
| 22.11.2022 | Another 50 million euros for CatalYm's anti-tumor antibody v... | Martinsried, Germany-based CatalYm has successfully closed a Series C financing of 50 million euros.... | bio-m.org/... |
| 22.11.2022 | CatalYm Closes EUR 50 Million Series C Financing to Expand a... | CatalYm today announced the close of a EUR 50 million (USD 49 million) Series C financing round. The... | brandoncap... |
| 22.11.2022 | CatalYm Closes EUR 50M Series C Financing | CatalYm, a Munich, Germany-based biotechnology company, raised €50M in Series C funding. The round ... | finsmes.co... |
| 01.03.2021 | CatalYm GmbH : Announces Key Management and Board Changes | DGAP-News: CatalYm GmbH / Key word(s): Personnel CatalYm Announces Key Management and Board Changes... | marketscre... |
| 03.01.2021 | CatalYm GmbH : Announces Key Management and Board Changes | DGAP-News: CatalYm GmbH / Key word(s): Personnel CatalYm Announces Key Management and Board Changes... | marketscre... |
| 11.11.2020 | CatalYm secures €50m Series B funding | - | vcbay.news... |
Show more